Activities of moxifloxacin against, and emergence of resistance in, Streptococcus pneumoniae and Pseudomonas aeruginosa in an in vitro pharmacokinetic model.
about
Suppression of Emergence of Resistance in Pathogenic Bacteria: Keeping Our Powder Dry, Part 1Antimicrobial drug resistance, regulation, and research.Pharmacodynamics of Ceftolozane plus Tazobactam Studied in an In Vitro Pharmacokinetic Model of InfectionOptimizing drug exposure to minimize selection of antibiotic resistance.In vitro pharmacodynamic models to determine the effect of antibacterial drugs.Mutant selection window in levofloxacin and moxifloxacin treatments of experimental pneumococcal pneumonia in a rabbit model of human therapy.Species differences in ciprofloxacin resistance among Gram-negative bacteria: can "anti-mutant" ratios of the area under the concentration-time curve to the MIC be achieved clinically?Searching for the Optimal Predictor of Ciprofloxacin Resistance in Klebsiella pneumoniae by Using In Vitro Dynamic Models.Enrichment of fluoroquinolone-resistant Staphylococcus aureus: oscillating ciprofloxacin concentrations simulated at the upper and lower portions of the mutant selection window.Predicting and preventing antimicrobial resistance utilizing pharmacodynamics: part II Gram-negative bacteria.Pharmacodynamics of the antibacterial effect of and emergence of resistance to doripenem in Pseudomonas aeruginosa and Acinetobacter baumannii in an in vitro pharmacokinetic model.Mechanism of fluoroquinolone resistance is an important factor in determining the antimicrobial effect of gemifloxacin against Streptococcus pneumoniae in an in vitro pharmacokinetic model.Predictors of bacterial resistance using in vitro dynamic models: area under the concentration-time curve related to either the minimum inhibitory or mutant prevention antibiotic concentration.Determining β-lactam exposure threshold to suppress resistance development in Gram-negative bacteria.Differences in the pharmacodynamics of ceftaroline against different species of Enterobacteriaceae studied in an in vitro pharmacokinetic model of infection.Pharmacodynamics of moxifloxacin against anaerobes studied in an in vitro pharmacokinetic model.Pharmacodynamic assessment based on mutant prevention concentrations of fluoroquinolones to prevent the emergence of resistant mutants of Streptococcus pneumoniae.Pharmacodynamics of razupenem (PZ601) studied in an in vitro pharmacokinetic model of infection.Pharmacodynamics of telavancin studied in an in vitro pharmacokinetic model of infectionBacterial strain-to-strain variation in pharmacodynamic index magnitude, a hitherto unconsidered factor in establishing antibiotic clinical breakpoints.Pharmacodynamics of ceftaroline against Staphylococcus aureus studied in an in vitro pharmacokinetic model of infection.Pharmacodynamics of the antibacterial effect and emergence of resistance to tomopenem, formerly RO4908463/CS-023, in an in vitro pharmacokinetic model of Staphylococcus aureus infection.Testing the mutant selection window hypothesis with Staphylococcus aureus exposed to linezolid in an in vitro dynamic model.
P2860
Q26771850-EE89789A-816A-4D09-A438-14A9C20B85CAQ36026412-20554FB0-78F4-4EE2-A9B6-9ABDDC5B2D21Q36438924-256B2776-46EF-4D0F-BABC-30E8E1AFDFB8Q36903693-9CD482B0-EC85-43AB-ABF2-097B5A68A645Q37660762-033488B8-13FC-431C-8FC7-EEBEC53C1518Q37733449-0F2E1DC9-84B2-4180-ADF2-707B901A12E4Q38740127-73A574FC-1528-4DFC-832E-9AEBEDC53AA8Q38740720-772B69DE-9230-47BD-92BE-0F5ACACB03F8Q38899404-A309FF81-30FD-4EF3-B287-6D95DAB9D906Q39293585-949D2FD0-CA31-49DA-A709-787A1783FA07Q39599930-AC2BEB1A-03A6-4CA2-B589-13594233D652Q39731782-D239D8FE-1A45-4A05-8127-4286FCE62799Q40253055-EF439C95-F616-48C8-98F2-CDC52A77B7C8Q40346786-17AB28E7-E905-4159-AB4F-B3D69B45F2F0Q40804939-64B8ED4B-DBFB-46F9-A08A-F9FC33E87983Q41832949-C5E98C96-7D04-48C7-B3EE-261FFF889A99Q41854694-99A2929E-77B9-48E9-9E91-CBB66E1BD268Q41864984-67578C78-A2F0-41C6-8AC3-63543333976CQ41925060-FAFB4836-C7F4-4B42-8308-40C9FEC70EB6Q42116787-87167EB3-6105-47EF-B655-E5F1AF1CB3AFQ42275442-E3BBEF13-D9ED-4FF2-B944-AB8EC7F23302Q43111815-47BDD9B1-2DF7-4683-BF28-1C60FE37A91DQ49578631-427EB895-4476-4B22-B51C-9083408EE366
P2860
Activities of moxifloxacin against, and emergence of resistance in, Streptococcus pneumoniae and Pseudomonas aeruginosa in an in vitro pharmacokinetic model.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
2003年學術文章
@zh
2003年學術文章
@zh-hant
name
Activities of moxifloxacin aga ...... n vitro pharmacokinetic model.
@en
Activities of moxifloxacin aga ...... n vitro pharmacokinetic model.
@nl
type
label
Activities of moxifloxacin aga ...... n vitro pharmacokinetic model.
@en
Activities of moxifloxacin aga ...... n vitro pharmacokinetic model.
@nl
prefLabel
Activities of moxifloxacin aga ...... n vitro pharmacokinetic model.
@en
Activities of moxifloxacin aga ...... n vitro pharmacokinetic model.
@nl
P2093
P2860
P1476
Activities of moxifloxacin aga ...... n vitro pharmacokinetic model.
@en
P2093
Alasdair P MacGowan
Chris A Rogers
H Alan Holt
Karen E Bowker
P2860
P304
P356
10.1128/AAC.47.3.1088-1095.2003
P407
P577
2003-03-01T00:00:00Z